PT3290023T - Composição farmacêutica de libertação sustentada contendo rivastigmina - Google Patents
Composição farmacêutica de libertação sustentada contendo rivastigminaInfo
- Publication number
- PT3290023T PT3290023T PT167867324T PT16786732T PT3290023T PT 3290023 T PT3290023 T PT 3290023T PT 167867324 T PT167867324 T PT 167867324T PT 16786732 T PT16786732 T PT 16786732T PT 3290023 T PT3290023 T PT 3290023T
- Authority
- PT
- Portugal
- Prior art keywords
- rivastigmine
- pharmaceutical composition
- release pharmaceutical
- containing sustained
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150058759A KR101990951B1 (ko) | 2015-04-27 | 2015-04-27 | 리바스티그민 함유 서방출 의약조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3290023T true PT3290023T (pt) | 2021-03-24 |
Family
ID=57199589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT167867324T PT3290023T (pt) | 2015-04-27 | 2016-04-27 | Composição farmacêutica de libertação sustentada contendo rivastigmina |
Country Status (21)
Country | Link |
---|---|
US (1) | US10835497B2 (pt) |
EP (1) | EP3290023B1 (pt) |
JP (1) | JP6787928B2 (pt) |
KR (1) | KR101990951B1 (pt) |
CN (1) | CN107530290B (pt) |
AU (1) | AU2016255302B2 (pt) |
BR (1) | BR112017022478B1 (pt) |
CA (1) | CA2984235C (pt) |
CY (1) | CY1124339T1 (pt) |
DK (1) | DK3290023T3 (pt) |
ES (1) | ES2860694T3 (pt) |
HR (1) | HRP20210434T1 (pt) |
HU (1) | HUE053816T2 (pt) |
LT (1) | LT3290023T (pt) |
MX (1) | MX2017013481A (pt) |
PL (1) | PL3290023T3 (pt) |
PT (1) | PT3290023T (pt) |
RS (1) | RS61548B1 (pt) |
RU (1) | RU2727721C2 (pt) |
SI (1) | SI3290023T1 (pt) |
WO (1) | WO2016175546A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102209420B1 (ko) * | 2019-03-08 | 2021-01-29 | 에이치엘비제약 주식회사 | 리바스티그민의 일정한(0-차) 방출형 경구용 서방성 정제 조성물 |
CN112546037A (zh) * | 2020-12-08 | 2021-03-26 | 苏州大学 | 卡巴拉汀在制备抗辐射药中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69923200T2 (de) | 1998-10-01 | 2005-12-22 | Novartis Ag | Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe |
JP2003507416A (ja) * | 1999-08-26 | 2003-02-25 | エラン コーポレイション ピーエルスィー | 医薬製剤 |
WO2001013898A2 (en) * | 1999-08-26 | 2001-03-01 | Elan Corporation, Plc. | Pharmaceutical formulations with different release times |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
US20050163847A1 (en) * | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
RU2390354C2 (ru) * | 2004-12-27 | 2010-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения |
JP2008525313A (ja) * | 2004-12-27 | 2008-07-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬の安定化方法 |
US9713592B2 (en) * | 2005-04-06 | 2017-07-25 | Mallinckrodt Llc | Matrix-based pulse release pharmaceutical formulation |
EP3703058A1 (en) * | 2005-11-29 | 2020-09-02 | Children's Hospital Medical Center | A method of selecting a medication for a patient |
US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
AU2006343596A1 (en) * | 2006-05-12 | 2007-11-22 | Shire Llc | Controlled dose drug delivery system |
US8632805B2 (en) * | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
KR101573889B1 (ko) | 2009-10-09 | 2015-12-04 | 영진약품공업주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
WO2011123496A1 (en) | 2010-03-31 | 2011-10-06 | Supernus Pharmaceuticals, Inc. | Formulations of mazindol |
CN108653226A (zh) * | 2013-03-15 | 2018-10-16 | 韩国联合制药株式会社 | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 |
-
2015
- 2015-04-27 KR KR1020150058759A patent/KR101990951B1/ko active IP Right Grant
-
2016
- 2016-04-27 HU HUE16786732A patent/HUE053816T2/hu unknown
- 2016-04-27 MX MX2017013481A patent/MX2017013481A/es unknown
- 2016-04-27 US US15/569,693 patent/US10835497B2/en active Active
- 2016-04-27 PT PT167867324T patent/PT3290023T/pt unknown
- 2016-04-27 JP JP2017555575A patent/JP6787928B2/ja active Active
- 2016-04-27 CA CA2984235A patent/CA2984235C/en active Active
- 2016-04-27 CN CN201680024737.4A patent/CN107530290B/zh active Active
- 2016-04-27 EP EP16786732.4A patent/EP3290023B1/en active Active
- 2016-04-27 AU AU2016255302A patent/AU2016255302B2/en active Active
- 2016-04-27 WO PCT/KR2016/004380 patent/WO2016175546A2/ko active Application Filing
- 2016-04-27 DK DK16786732.4T patent/DK3290023T3/da active
- 2016-04-27 PL PL16786732T patent/PL3290023T3/pl unknown
- 2016-04-27 BR BR112017022478-0A patent/BR112017022478B1/pt active IP Right Grant
- 2016-04-27 ES ES16786732T patent/ES2860694T3/es active Active
- 2016-04-27 SI SI201631161T patent/SI3290023T1/sl unknown
- 2016-04-27 LT LTEP16786732.4T patent/LT3290023T/lt unknown
- 2016-04-27 RS RS20210290A patent/RS61548B1/sr unknown
- 2016-04-27 RU RU2017136567A patent/RU2727721C2/ru active
-
2021
- 2021-03-16 HR HRP20210434TT patent/HRP20210434T1/hr unknown
- 2021-04-14 CY CY20211100324T patent/CY1124339T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20180125785A1 (en) | 2018-05-10 |
LT3290023T (lt) | 2021-03-25 |
RU2017136567A (ru) | 2019-05-27 |
CA2984235A1 (en) | 2016-11-03 |
KR101990951B1 (ko) | 2019-06-20 |
SI3290023T1 (sl) | 2021-08-31 |
CN107530290B (zh) | 2021-04-27 |
JP2018514530A (ja) | 2018-06-07 |
RU2017136567A3 (pt) | 2019-09-19 |
DK3290023T3 (da) | 2021-04-12 |
CA2984235C (en) | 2023-02-21 |
HUE053816T2 (hu) | 2021-07-28 |
CN107530290A (zh) | 2018-01-02 |
WO2016175546A2 (ko) | 2016-11-03 |
JP6787928B2 (ja) | 2020-11-18 |
EP3290023A4 (en) | 2018-12-19 |
US10835497B2 (en) | 2020-11-17 |
EP3290023A2 (en) | 2018-03-07 |
AU2016255302B2 (en) | 2021-03-04 |
BR112017022478A2 (pt) | 2018-07-10 |
CY1124339T1 (el) | 2022-07-22 |
KR20160127405A (ko) | 2016-11-04 |
WO2016175546A3 (ko) | 2016-12-22 |
PL3290023T3 (pl) | 2021-08-30 |
EP3290023B1 (en) | 2021-02-17 |
BR112017022478B1 (pt) | 2023-11-21 |
AU2016255302A1 (en) | 2017-12-07 |
RU2727721C2 (ru) | 2020-07-23 |
RS61548B1 (sr) | 2021-04-29 |
MX2017013481A (es) | 2018-05-17 |
HRP20210434T1 (hr) | 2021-04-30 |
ES2860694T3 (es) | 2021-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265360B (en) | Pharmaceutical composition | |
IL265260B (en) | pharmaceutical preparations | |
GB201506658D0 (en) | Pharmaceutical compounds | |
GB201504675D0 (en) | Pharmaceutical compounds | |
GB201517217D0 (en) | Pharmaceutical compounds | |
GB201506660D0 (en) | Pharmaceutical compounds | |
GB201517216D0 (en) | Pharmaceutical compounds | |
IL262654A (en) | Pharmacy preparation | |
IL265349A (en) | Pharmaceutical composition | |
HK1246641A1 (zh) | 緩釋性醫藥組合物 | |
GB201506933D0 (en) | Pharmaceutical compounds | |
GB201502567D0 (en) | Pharmaceutical compounds | |
IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
GB201521462D0 (en) | Pharmaceutical composition | |
GB201515310D0 (en) | Pharmaceutical composition | |
HK1245073A1 (zh) | 藥物組合物 | |
PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
GB201615917D0 (en) | Pharmaceutical composition | |
GB201520862D0 (en) | Pharmaceutical composition | |
HUE053816T2 (hu) | Rivasztigmin tartalmú elnyújtott felszabadulású gyógyszerészeti készítmény | |
GB201615914D0 (en) | Pharmaceutical composition | |
GB201615910D0 (en) | Pharmaceutical composition | |
IL265436B (en) | Pharmacy preparation | |
HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
IL265428A (en) | Pharmaceutical composition |